Current Report Filing (8-k)
April 24 2020 - 8:13AM
Edgar (US Regulatory)
0001124140
false
0001124140
2020-04-21
2020-04-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 22, 2020
EXACT SCIENCES CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-35092
|
|
02-0478229
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
441 Charmany Drive
Madison, WI 53719
(Address of Principal Executive Offices)(Zip
Code)
Registrant’s telephone number, including
area code: 608-535-8815
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common
Stock, $0.01 par value per share
|
EXAS
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
|
On April 22, 2020, the Board of Directors of Exact Sciences
Corporation (the “Company”) appointed Freda Lewis-Hall, M.D., DFAPA to serve as a Class II director until the 2020
Annual Meeting of Stockholders.
Dr. Lewis-Hall served as Chief Patient Officer and Executive
Vice President of Pfizer Inc. (NYSE: PFE) from January 2019 to December 2019. She acted as a Senior Medical Advisor to the CEO
until her retirement in March 2020. From 2009 to December 2019, Dr. Lewis-Hall served as Pfizer’s Chief Medical Officer and
Executive Vice President. Prior to joining Pfizer in 2009, Dr. Lewis-Hall held various senior leadership positions including Chief
Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals, Inc., a biopharmaceutical company,
from 2008 to 2009, and Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Co. from 2003 to 2008.
Dr. Lewis-Hall serves on the board of directors of SpringWorks
Therapeutics, Inc. (NASDAQ: SWTX) and 1Life Healthcare, Inc. (NASDAQ: ONEM). From December 2014 to May 2017, she served on the
board of directors of Tenet Healthcare Corporation (NYSE: THC). Dr. Lewis-Hall currently serves on the board of fellows of The
Harvard School and the board of advisors of the Dell Medical School. She also serves as a member of the board of governors
for the Patient-Centered Outcomes Research Institute. Dr. Lewis-Hall earned a B.A. in Natural Sciences from Johns Hopkins University
and an M.D. from Howard University College of Medicine.
Dr. Lewis-Hall will receive compensation for her service
as a director in accordance with the Company’s Non-Employee Director Compensation Policy filed herewith as Exhibit 10.1
and incorporated herein by reference (the “Director Compensation Policy”). Pursuant to the Non-Employee Director
Compensation Policy, in connection with her initial appointment to the Board of Directors, Dr. Lewis-Hall received a stock
award valued at $375,000.
|
9.01.
|
Financial Statements and Exhibits.
|
Exhibits
The following exhibit is filed herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
EXACT SCIENCES CORPORATION
|
|
|
Date: April 24, 2020
|
By:
|
/s/ Jeffrey T. Elliott
|
|
|
Jeffrey T. Elliott
|
|
|
Chief Financial Officer
|
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Apr 2023 to Apr 2024